A Phase I clinical trial targeting RAS for aggressive tumors utilized Ang(1-7) as the primary anti-angiogenic agent; Ang(1-7) exerts this effect by specifically activating MasR, thereby inhibiting tumor angiogenesis [50]. This evidence concerns the gene MAS1L and neoplasm.